Myriad Genetics, Inc. to Post Q1 2025 Earnings of ($0.04) Per Share, Leerink Partnrs Forecasts (NASDAQ:MYGN)

Myriad Genetics, Inc. (NASDAQ:MYGN) – Equities research analysts at Leerink Partnrs reduced their Q1 2025 earnings estimates for shares of Myriad Genetics in a research report issued on Thursday, October 10th. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings of ($0.04) per share for the quarter, down from their previous forecast of ($0.02). The consensus estimate for Myriad Genetics’ current full-year earnings is ($0.34) per share. Leerink Partnrs also issued estimates for Myriad Genetics’ Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.11) EPS.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. The firm had revenue of $211.50 million during the quarter, compared to analysts’ expectations of $206.44 million. Myriad Genetics had a negative net margin of 19.35% and a negative return on equity of 5.64%. Myriad Genetics’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.21) earnings per share.

A number of other equities research analysts have also recently issued reports on the stock. Piper Sandler upped their price target on shares of Myriad Genetics from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Tuesday, August 13th. Morgan Stanley began coverage on shares of Myriad Genetics in a report on Thursday, September 19th. They set an “equal weight” rating and a $32.00 price target for the company. JPMorgan Chase & Co. upped their price target on shares of Myriad Genetics from $17.00 to $20.00 and gave the company an “underweight” rating in a report on Wednesday, August 7th. Scotiabank upped their price objective on shares of Myriad Genetics from $29.00 to $34.00 and gave the company a “sector outperform” rating in a research report on Tuesday, August 13th. Finally, TD Cowen upped their price objective on shares of Myriad Genetics from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $28.91.

Myriad Genetics Stock Up 4.2 %

MYGN stock opened at $25.10 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.78. Myriad Genetics has a 52-week low of $13.82 and a 52-week high of $29.30. The company has a 50-day moving average of $27.07 and a two-hundred day moving average of $24.59. The stock has a market capitalization of $2.27 billion, a price-to-earnings ratio of -8.90 and a beta of 1.91.

Institutional Trading of Myriad Genetics

Hedge funds have recently modified their holdings of the stock. Hexagon Capital Partners LLC grew its stake in shares of Myriad Genetics by 75.3% during the second quarter. Hexagon Capital Partners LLC now owns 1,143 shares of the company’s stock valued at $28,000 after purchasing an additional 491 shares during the last quarter. Innealta Capital LLC bought a new position in Myriad Genetics in the second quarter valued at approximately $36,000. GAMMA Investing LLC boosted its stake in Myriad Genetics by 34.1% in the third quarter. GAMMA Investing LLC now owns 1,620 shares of the company’s stock valued at $44,000 after acquiring an additional 412 shares during the last quarter. Point72 DIFC Ltd bought a new position in Myriad Genetics in the second quarter valued at approximately $60,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Myriad Genetics in the second quarter valued at approximately $82,000. 99.02% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Myriad Genetics news, CEO Paul J. Diaz sold 15,000 shares of the company’s stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $22.93, for a total transaction of $343,950.00. Following the sale, the chief executive officer now directly owns 962,378 shares of the company’s stock, valued at approximately $22,067,327.54. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Myriad Genetics news, CEO Paul J. Diaz sold 15,000 shares of the company’s stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $22.93, for a total transaction of $343,950.00. Following the sale, the chief executive officer now directly owns 962,378 shares of the company’s stock, valued at approximately $22,067,327.54. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Colleen F. Reitan sold 46,012 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $27.95, for a total transaction of $1,286,035.40. Following the sale, the director now directly owns 42,533 shares in the company, valued at $1,188,797.35. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,012 shares of company stock valued at $1,900,485 over the last quarter. Corporate insiders own 2.10% of the company’s stock.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.